Dr. Gregg Stanwood is currently accepting new graduate students.
Dr. Gregg Stanwood
Associate Professor of Biomedical Sciences & Neuroscience
- Biomedical Sciences
- We study how genes and environment contribute to the formation and function of brain circuits that mediate cognitive, motivational and emotional responses. Dysregulation of these processes during critical periods of maturation contributes to development of mental health and neurological disorders.
- Current Research
- We primarily work in mouse models of human disease and use pharmacological, behavioral, cell biological, and neuroanatomical methods. In one series of studies we are assessing the roles for dopamine D1 and D2 receptors in the differentiation of forebrain interneurons, and studying how loss and gain of function in the dopamine system leads to neuropsychiatric disorders later in life. In another project, we are focusing on an important insulin regulator in the brain, GLP-1, and how GLP-1 receptors can regulate drug reward, dopamine homeostasis, and responses to stress.
- Recent Publications
Anacker AMJ, Moran JT, Santarelli S, Forsberg CG, Rogers TD, Stanwood GD, Hall BJ, Delpire E, Veenstra-VanderWeele J, Saxe MD (2019). Enhanced Social Dominance and Altered Neuronal Excitability in the Prefrontal Cortex of Male KCC2b Mutant Mice. Autism Res, 12(5):732-743. PubMed Beerse ME, Van Lith T, Pickett SM, Stanwood GD (2019). Biobehavioral utility of mindfulness-based art therapy: Neurobiological underpinnings and mental health impacts. Exp Biol Med (Maywood), 245(2):122-130. PubMed Goldfarb SS, Stanwood GD, Flynn HA, Graham DL (2019). Developmental opioid exposures: Neurobiological underpinnings, behavioral impacts, and policy implications. Exp Biol Med (Maywood), 245(2):131-137. PubMed Davis GL, Stewart A, Stanwood GD, Gowrishankar R, Hahn MK, Blakely RD (2018). Functional coding variation in the presynaptic dopamine transporter associated with neuropsychiatric disorders drives enhanced motivation and context-dependent impulsivity in mice. Behav Brain Res, 61-69. PubMed Toki S, Goleniewska K, Reiss S, Zhang J, Bloodworth MH, Stier MT, Zhou W, Newcomb DC, Ware LB, Stanwood GD, Galli A, Boyd KL, Niswender KD, Peebles RS Jr (2018). Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol, 142(5):1515-1528. PubMed Muller CL, Anacker AM, Rogers TD, Goeden N, Keller EH, Forsberg CG, Kerr TM, Wender C, Anderson GM, Stanwood GD, Blakely RD, Bonnin A, Veenstra-VanderWeele J (2017). Impact of maternal serotonin transporter genotype on placental serotonin, fetal forebrain serotonin, and neurodevelopment. Neuropsychopharmacology, 42(2):427-436. PubMed Martin MM, Graham DL, McCarthy DM, Bhide PG, Stanwood GD (2016). cocaine-induced neurodevelopmental deficits and underlying mechanisms. Birth Defects Res C Embryo Today, 108(2):147-73. PubMed Reddy IA, Pino JA, Weikop P, Osses N, Sørensen G, Bering T, Valle C, Bluett RJ, Erreger K, Wortwein G, Reyes JG, Graham D, Stanwood GD, Hackett TA, Patel S, Fink-Jensen A, Torres GE, Galli A (2016). Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels. Transl Psychiatry, 6(5):e809. PubMed Frederick AL, Yano H, Trifilieff P, Vishwasrao HD, Biezonski D, Mészáros J, Urizar E, Sibley DR, Kellendonk C, Sonntag KC, Graham DL, Colbran RJ, Stanwood GD, Javitch JA (2015). Evidence against dopamine D1/D2 receptor heteromers. Mol Psychiatry, 20(11):1373-85. PubMed Graham DL, Buendia MA, Chapman MA, Durai HH, Stanwood GD (2015). Deletion of Galphaq in the telencephalon alters specific neurobehavioral outcomes. Synaps, 69(9):434-45. PubMed Graham DL, Durai HH, Garden JD, Cohen EL, Echevarria FD, Stanwood GD (2015). Loss of dopamine D2 receptors increases parvalbumin-positive interneurons in the anterior cingulate cortex. ACS Chem Neurosci, 6(2):297-305. PubMed Ross EJ, Graham DL, Money KM, Stanwood GD (2015). Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology, 40(1):61-87. PubMed Sørensen G, Reddy IA, Weikop P, Graham DL, Stanwood GD, Wortwein G, Galli A, Fink-Jensen A (2015). The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol Behav, 262-8. PubMed Sørensen G, Reddy IA, Weikop P, Graham DL, Stanwood GD, Wortwein G, Galli A, Fink-Jensen A (2015). The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol Behav, 262-268. PubMed